Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of intrathecal or intraventricular topotecan in treating recurrent, progressive, or refractory cancer that is metastatic to the lining around the brain.

Key facts

Study ID

NCT00025311

Run by

NYU Langone Health

Starts

2001-05-01

Last updated by the study team

2012-11-09

Who can join

Age: any, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• CHU Pitie-Salpetriere — Paris, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.